Irinotecan
Cholangiocarcinoma of the Gallbladder
University of ChicagoSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Cholangiocarcinoma of the Gallbladder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM University of Chicago | Phase 2 | B |
Eloxatin University of Chicago | Phase 2 | B |
Calcium folinate pentahydrate University of Chicago | Phase 2 | B |
Cediranib National Cancer Institute (NCI) | Phase 2 | CCC |
Ixabepilone National Cancer Institute (NCI) | Phase 2 | CCC |
View all 15 →
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →